Industry News

MAAA-1162a (Deruxtecan, MC-GGFG-DXd) is a drug-linker complex of detrastuzumab (DS-8201a), formed by DXd (MAAA-1181a, payload) and maleimide-tetrapeptide linker (MC-GGFG) through chemical coupling.

The synthesis of doxercalciferol (1α-hydroxyvitamin D₂) usually starts with vitamin D₂ (ergocalciferol) as the starting material, and introduces the 1α-hydroxyl group through selective protection, oxidation, and photoisomerization

This article examines why your reference standard for Sucrose Octasulfate-Aluminum Complex (Orforglipron Impurity 18) must meet the highest standards of purity, characterization, and regulatory compliance, and explores how Cosper Pharma Tech Co., Ltd. can support your impurity profiling and ANDA filing journey.

​Migalastat is an innovative oral therapy designed for the treatment of Fabry disease, a rare genetic lysosomal storage disorder that affects multiple organs and significantly reduces quality of life. Unlike traditional enzyme replacement therapies, Migalastat works by stabilizing certain forms of the body’s own enzyme, allowing it to function more effectively.

Osimertinib has transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC), especially those carrying EGFR mutations. Compared with traditional chemotherapy, this targeted therapy offers improved survival rates, better brain penetration, and fewer severe systemic toxicities. However, many patients and healthcare buyers still face questions regarding effectiveness, safety, resistance mechanisms, affordability, and long-term outcomes.